American Firm Moderna Says Anti-Covid19 Vaccine is 94.5% Effective in Phase 3 Clinical Trials

American Firm Moderna Says Anti-Covid19 Vaccine is 94.5% Effective in Phase 3 Clinical Trials
Monday 16 November 2020 - 16:14

US biotech firm Moderna has said in a press release on Monday that its mRNA-based candidate anti-Covid19 vaccine has proven to be 94.5 percent effective in phase three clinical trials.

“This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5%,” Moderna added.

The biotech company said that the vaccine was “generally well tolerated,” although side effects such as fatigue, myalgia, and headaches were reported in a minority of participants.

“This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” Stephane Bancel, Moderna’s chief executive officer, said in the press release.

add your comment

Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.

News
Dutch lawmakers challenge Google over racist search suggestions targeting Moroccans
Wednesday 18 November 2026 - 20:00

Dutch lawmakers challenge Google over racist search suggestions targeting Moroccans

Economy
Morocco’s GDP per capita set to exceed $5,000 for first time in 2026, IMF forecasts
Wednesday 18 November 2026 - 18:00

Morocco’s GDP per capita set to exceed $5,000 for first time in 2026, IMF forecasts

News
King Mohammed VI launches roadmap to expand Morocco’s defense industry
Wednesday 18 November 2026 - 15:53

King Mohammed VI launches roadmap to expand Morocco’s defense industry

News
Morocco, UAE sign security cooperation agreement to strengthen intelligence sharing
Wednesday 18 November 2026 - 14:20

Morocco, UAE sign security cooperation agreement to strengthen intelligence sharing